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with revascularization up to 24 months, and in the TOSCA-2
(Total Occlusion Study of Canada) trial (24), a substudy of the
OAT study, there was a trend toward more favorable remodeling.
The results of the OAT study do not prove or disprove the
benefits of late revascularization in patients similar to the patients
in the OAT study and certainly do not apply to the entirety of
post-AMI patients. Unfortunately, despite the efforts of investi-
gators like the OAT Investigators, only 3,560 patients have been
randomized to date, and they may not be enough to draw
meaningful conclusions and/or identify subgroups of patients with
greatest benefit or risk from late revascularization.
We thank Dr. Džavı´k and colleagues for this opportunity to
clarify that our analysis was not designed to prove or disprove the
findings of the OAT study, which likely applies to a minority of
patients after AMI. Instead, we set out to analyze all available
evidence and demonstrated the benefit of late revascularization of
the IRA late after AMI.
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Percutaneous Coronary
Intervention or Coronary Artery
Bypass Graft for Unprotected
Left Main Coronary Artery
Disease: The Endless Debate
The “state-of-the art” paper written by Taggart et al. (1) calls into
question the current evidence in support of percutaneous coronary
intervention (PCI) for the treatment of unprotected left main stem
disease. In view of the fact that current guidelines still indicate
coronary artery bypass grafting (CABG) as the “standard of care,”
the authors conclude that the use of drug-eluting stents (DES) in
“off-label” cases should be discouraged and that good surgical
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candidates with unprotected left main coronary artery (ULMCA)
disease should undergo surgical revascularization. These conclu-
sions, although absolutely reasonable, raise 2 questions: 1) Is
CABG really proven to perform better than PCI in this subset of
patients? 2) Is CABG to be recommended in all good surgical
candidates?
In an attempt to justify their conclusion, the authors presented
6 studies conducted in patients with ULMCA disease who had
undergone CABG. Of note, none of these studies had clinical
follow-up periods of longer than 2 years, and only 2 out of 6 had
a clinical follow-up longer than 1 year (Lu et al. [2] and Yeatman
et al. [3]). The mortality rate of 5% to 6% reported by these studies
is truly encouraging. However, the authors did not mention the
impressive occurrence of post-procedural morbidity in these pa-
tients. In the study conducted by Lu et al. (2) on 1,197 patients
who underwent CABG for ULMCA, the rates of in-hospital
adverse events were the following: mortality 2.8%, renal failure
3.9%, gastrointestinal complications 3.6%, stroke 2.2%, post-
procedural myocardial infarction 7.1%, reoperation for bleeding
2.8%, sternal wound infection 4.2%, chest infection 5.3%, venti-
lation 48 h 6%, stay after operation 14 days 9.3%. The
incidence of death in patients undergoing CABG for ULMCA
disease was reported to be 11.3% at 1 year in the Cleveland Clinic
Foundation Data (4), 12.8% at 3 yeas in the New York Bypass
Surgery Registry (5), 13.2% at 5 years in the study conducted by
d’Allonnes et al. (6), and 22.6% at 5 years in the Duke Cardiology
Database (7). These results are far worse than those reported by
the authors and do not appear to be superior to those reported in
several PCI studies.
In discussing the experience with bare-metal stents (BMS), the
authors presented the results from earlier PCI studies that enrolled
almost exclusively high-risk patients. The “poor” late outcomes
after ULMCA stenting with BMS are compared with the excellent
results obtained in the SoS (Stent or Surgery) trial. This compar-
ison of “apples versus pears,” i.e., left main disease in high-risk
patients versus 2- to 3-vessel disease in stable patients, is not a
proper scientific argument. In that specific study, the comparison
between CABG and PCI resulted in no statistically significant
differences in terms of death, myocardial infarction, or stroke at
1-year follow-up (8). With regard to DES implantation, the
authors describe a selection of studies that presents an important
nonhomogeneity in terms of trial design: consecutive (e.g., Valgi-
migli et al. [9], Lee et al. [10]) vs. selective (de Lezo et al. [11])
patient enrollment and, in some studies, the use of DES was not
exclusive (e.g., approximately 40% of patients from the Bologna
Registry received BMS). Moreover, the authors did not take into
account the importance and influential outcomes of the various
stenting techniques used for distal left main disease.
It therefore seems difficult to draw any conclusions from the
pooling of these results and, furthermore, compare them with the
outcomes obtained in the surgical literature. In the DELFT
(Drug Eluting stent for LeFT main) registry (12), the 3-year
incidence of cardiac death, target vessel revascularization, and
major adverse cardiovascular events (MACE) in the elective
subgroup was 6.2%, 16%, and 30.5%, respectively. Recent
studies conducted on patients with ULMCA who underwent
surgical revascularization reported a similar incidence of death,
a lower incidence of TVR, but an apparently greater incidence
of MACE (9,13).
Additionally, it was noted by the authors that distal left main
disease is a major and independent predictor of MACE at
mid-term follow-up (9) and argued that: “the precise anatomical
location and complexity of left main stenosis . . . have negligible
influence on the success of CABG.” Two issues deserve further
clarification with respect to this statement: 1) In patients under-
going PCI, distal left main disease is associated with a higher risk
for reintervention but not necessarily death or myocardial infarc-
tion, which are predominantly affected by surgical risk status. 2) To
the best of our knowledge, there are no data supporting the notion
that outcomes after surgery are not affected by the location of the
lesion within the left main stem. Distal left main disease may
simply be a marker of severe, diffuse coronary disease and, as such,
carry with it a worse prognosis irrespective of the final revascular-
ization strategy.
In all major institutions, current standard approach to patients
presenting with significant ULMCA disease is to have them
evaluated by both interventional cardiologists and cardiac surgeons
and to reach the decision to opt for PCI or surgery by consensus,
on the basis of: 1) hemodynamic conditions; 2) lesion character-
istics; 3) vessel size; 4) the presence of comorbidities; 5) quality of
arterial and/or venous conduits for grafting; and 6) patient and/or
referring physician preferences. Patients are always fully informed
about the potential risks and outcomes of both the surgical and the
percutaneous approaches. Stating that “patients are influenced into
making a pre-ordained choice” and that cardiologists “instigate”
patients in making these choices is speculative.
Should all good candidates for surgery go to surgery and poor
candidates to PCI? So far, there is no strong evidence that one
approach is better than the other in terms both of clinical outcomes
and quality of life (QoL). A recent meta-analysis by Bravata et al.
(14) of 23 randomized controlled trials showed no difference
between PCI and CABG in terms of mortality at 10 years’
follow-up. Health-related QoL is of particular value in coronary
artery disease, because the objective of intervention is not only to
avoid clinical adverse outcomes but also to relieve symptoms and
improve function and ability to participate in daily activities.
Long-term studies comparing QoL related to these 2 therapeutic
strategies are not available but the results coming from the
available literature reported so far no major differences (15–18).
Current guidelines still recommend surgical revascularization as
the primary procedure in ULMCA patients, but considering them
as “the body of criminal law” is not always appropriate. Guidelines
are dynamic and in constant flux and have to be updated according
to new evidences coming from clinical experience, and not vice-
versa. It is important to realize that new-generation DES approved
for clinical use, new technical strategies, and prolonged dual-
antiplatelet treatment have significantly decreased the risk of
adverse events (including late in-stent thrombosis) after PCI.
Randomized clinical trials are necessary to shine a light on this
endless debate. The LEMANS trial (19) is the only reported
randomized trial comparing PCI versus CABG for ULMCA
disease. The increased short-term complication rate in the CABG
group appeared to be minimized by stressing similar 1-year
MACE results in the 2 groups. Moreover, no late in-stent
thrombosis occurred both in the BMS and in the DES groups,
demonstrating that percutaneous treatment of ULMCA is safe.
Results of the complete SYNTAX (TAXUS Drug-Eluting Stent
Versus Coronary Artery Bypass Surgery for the Treatment of Nar-
rowed Arteries) study, which enrolled 700 randomized patients with
ULMCA disease, will be presented at the 2008 European Society of
Cardiology congress. Until then, judicious individual assessment of
each patient should prevail, that is to say, we should keep trying to
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treat patients—that do not fit in the current recommendations—
according our current clinical experience and judgment.
“On the mountains of truth you can never climb in vain: either you
will reach a point higher up today, or you will be training your
powers so that you will be able to climb higher tomorrow.”
Friedrich Nietzsche (20)
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Reply
We are grateful to Dr. Meliga and colleagues for their interest in
our article (1). They raise several important issues that we will
address in a similar order.
The first issue deals with mortality and morbidity after coronary
artery bypass grafting (CABG). As referenced in our article (1), the
mortality for all 5,003 patients with left main stem stenosis
undergoing CABG in the United Kingdom in 2003 was 3% (and
2% in 17,000 without left main stem [LMS] stenosis and 1% in
3,102 patients in the ART [Arterial Revascularisation] trial).
Because enough is known about post-CABG complications, risk
models have been developed to reliably predict their occurrence,
whereas similar data are quite lacking in the percutaneous coronary
intervention (PCI) domain.
In addition, although all postoperative morbidity is unsatisfac-
tory, the reality is that, with the exception of stroke (1% to 2%),
most of it is self-limiting and of little consequence to the patient
over the long term. To equate early postoperative morbidity to the
reduced survival and marked increase in the need for reintervention
with PCI over the long term is arguably a false economy.
Furthermore, long-term mortality from CABG (as well as PCI)
may also reflect other co-existing morbidities, rather than being
attributable to ischemic heart disease.
With regard to bare-metal stents, we stated explicitly that
superior results were obtained in lower-risk patients and that, as
for CABG, the results of PCI would also be disadvantaged by
greater-risk patients. Although Dr. Meliga and colleagues state
that there was no significant difference in mortality between
CABG and PCI in the SoS (Stent or Surgery) trial at 1 year, it
should be noted that, at 5-year follow-up in this study (2), there
was a significant reduction in the risk of mortality with CABG
(6.6%) versus PCI (10.9%), reinforcing the well-known observa-
tion that the benefit of CABG often accrues with time. We agree
with Dr. Meliga and colleagues that substantial heterogeneity
among drug-eluting stent trials precludes pooling them together.
Accordingly, we did not perform a meta-analysis. Our aim was
simply to present all the published studies in the literature.
The complexity and precise anatomical location of distal left
main stem disease, along with its frequently associated multivessel
coronary disease, is not relevant during CABG because bypass
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